

Over 30 million adults suffer from Cardiovascular Disease (CVD) in India. Due to changes in lifestyle and economic conditions, the prevalence of risk factors for coronary heart disease has rapidly increased.

The overall incidence of heart disease has doubled in India over the last 20 years with the trend expecting to continue. A combination of clinical, biochemical [insulin resistance, lower adiponectin and higher C-reactive protein (CRP) levels], and metabolic aberrations [raised triglycerides (TGs), low- and high-density lipoprotein-cholesterol (HDL-c)] predispose Indians to higher CVD risks. More than 60% of coronary artery disease in Indians cannot be attributed to these commonly known risk factors.



Ischemic heart diseases accounted for 1215.4 thousand deaths in India in the year 2012, thereby making it the leading cause of death in India. The data recorded in 2010 stated that non-communicable diseases accounted for nearly 53% deaths in India, of which 24% are due to CVD. According to the National Interventional Council, Cardiological Society of India, 24.8 million coronary interventions were performed in 2014 and 31.1 million stents were implanted. The stent market in India is expected to triple in numbers by 2021.

Our Sites and Investigators

Our access to the most prominent cardiology site and investigators ensures a large and diverse patient pool along with the most up-to-date lines of medical treatment. We ensure that clinical trials are conducted according to ICH-GCP guidelines meet the highest standards of ethics and integrity.

Common cardiac diseases seen in India are hypertension, coronary artery disease, arrhythmias and congenital heart disease

CITIES	SITES	INVESTIGATORS
Delhi/ NCR	14	30
Mumbai	15	32
Kolkata	12	20
Bangalore	15	25
Chennai	10	22
Hyderabad	9	15
Pune	8	12
Jaipur	6	10
Ahmedabad	6	15
Nagpur	4	6
Others	26	43
Total	125	230



INDICATION	PHASE
CAD in diabetes	IV
Dyslipidemia	III
Hypertension	III
Hypertension	III
Hypertension	III
Atrial Fibrillation	III
Heart Failure	III

ELS experience - Cardiovascular Studies

Excel Life Sciences (ELS) is India's premier clinical trial and site management organization with extensive regulatory and clinical trials expertise. ELS has conducted over 40 studies for FDA submission and has undergone successful FDA and EMEA audits. We lead a network of ICH-GCP compliant investigators across 30 cities. Excel Life Sciences has offices in Boston, Chicago, New Delhi, and Research Triangle Park, NC.

USA +1 – 877 – EXCELOK (877) 392 – 3565 INDIA +91 120 4022 600

E-MAIL excel@excellifesciences.com WEB SITE www.excellifesciences.com